Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2210-2. doi: 10.1158/1055-9965.EPI-06-1065.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticarcinogenic Agents / adverse effects
  • Anticarcinogenic Agents / therapeutic use
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / prevention & control*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Postmenopause
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / therapeutic use*
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use*

Substances

  • Anticarcinogenic Agents
  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Raloxifene Hydrochloride